Mraz, Marek <br/><br/>
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.  [electronic resource] 

 -  British journal of haematology  Oct 2011 
 - 53-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2011.08794.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antibodies, Monoclonal, Murine-Derived--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>B-Lymphocytes--drug effects<br/>Bone Marrow Cells--physiology<br/>Cell Adhesion--drug effects<br/>Coculture Techniques<br/>Drug Resistance, Neoplasm--drug effects<br/>Humans<br/>Integrin alpha4beta1--antagonists & inhibitors<br/>Lymphoma, B-Cell--drug therapy<br/>Natalizumab<br/>Rituximab<br/>Stromal Cells--physiology<br/>Tumor Cells, Cultured<br/>Tumor Microenvironment--drug effects